Innate Pharma S.A. (IPHA)

Innate Pharma Revenue

Innate Pharma had revenue of 4.86M EUR in the half year ending June 30, 2025, a decrease of -87.91%. This brings the company's revenue in the last twelve months to 12.64M, down -62.60% year-over-year. In the year 2024, Innate Pharma had annual revenue of 20.12M, down -67.36%.

• Revenue (ttm): 12.64M EUR
• Revenue Growth: -62.60%
• P/S Ratio: 11.74
• Revenue / Employee: 69,812 EUR
• Employees: 181
• Market Cap: 174.16M USD

Revenue Chart

* This company reports financials in EUR.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	20.12M	-41.52M	-67.36%
Dec 31, 2023	61.64M	3.97M	6.88%
Dec 31, 2022	57.67M	32.97M	133.47%
Dec 31, 2021	24.70M	-45.07M	-64.60%
Dec 31, 2020	69.77M	-15.68M	-18.35%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.